Liberty Analytics Co. Initiates Independent Research Coverage on Encorium Group, Inc.
01 April 2010 - 12:15AM
Liberty Analytics Co., a leading provider of large, small- and
micro-cap independent investment research, today initiated coverage
on Encorium Group, Inc. (Nasdaq:ENCO). Liberty Analytics is
currently offering a complimentary trial subscription. To view our
research, go to: www.libertyanalyticsco.com.
About LAC:
Liberty Analytics Co. is a leading provider of independent
investment research in North America. Our services include research
analysis on the large, small- and micro-cap markets, real-time news
and financial data, market commentary and the LAC newsletter.
Liberty Analytics' staff of large and small-cap investment
professionals is dedicated to providing the market's investment
community with the tools and avenues necessary to make the
important investment decisions. To view our research reports on a
complimentary trial basis and take advantage of our other services,
go to www.libertyanalyticsco.com and click on the complimentary
trial subscription button on our home page, or go directly to our
registration page at www.libertyanalyticsco.com/signup.php.
About Encorium Group, Inc. (Nasdaq:ENCO)
Encorium Group, Inc. (Nasdaq:ENCO) is a clinical research
organization (CRO), which is engaged in the design and management
of clinical trials for the pharmaceutical, biotechnology and
medical device industries.
LAC Disclosure:
Libertyanalyticsco.com is not a registered investment advisor
and nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. Liberty Analytics has
not been compensated by any of the above-mentioned companies.
Please read our report and visit our Web site,
www.libertyanalyticsco.com, for complete risks and disclosures.
CONTACT: Liberty Analytics
Kevin Mix
480-626-1850
info@libertyanalyticsco.com